EA201890080A1 - Анализ модуляторов - Google Patents
Анализ модуляторовInfo
- Publication number
- EA201890080A1 EA201890080A1 EA201890080A EA201890080A EA201890080A1 EA 201890080 A1 EA201890080 A1 EA 201890080A1 EA 201890080 A EA201890080 A EA 201890080A EA 201890080 A EA201890080 A EA 201890080A EA 201890080 A1 EA201890080 A1 EA 201890080A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tnf
- modulators
- analysis
- compounds
- conformation
- Prior art date
Links
- 238000004458 analytical method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Abstract
В заявке описано, что определенные соединения связываются с TNF и стабилизируют конформацию тримерного TNF, который связывается с рецептором TNF. Соответственно, указанные соединения можно использовать в качестве модуляторов TNF. Также описан новый метод анализа для идентификации соединений с указанным механизмом действия.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1510758.4A GB201510758D0 (en) | 2015-06-18 | 2015-06-18 | Novel TNFa structure for use in therapy |
PCT/EP2015/074524 WO2016202413A1 (en) | 2015-06-18 | 2015-10-22 | Modulator assay |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201890080A1 true EA201890080A1 (ru) | 2018-07-31 |
Family
ID=53784155
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201890081A EA201890081A1 (ru) | 2015-06-18 | 2015-10-22 | Механизм действия |
EA201890078A EA201890078A1 (ru) | 2015-06-18 | 2015-10-22 | Антитело |
EA201890082A EA201890082A1 (ru) | 2015-06-18 | 2015-10-22 | Эпитоп антитела |
EA201890080A EA201890080A1 (ru) | 2015-06-18 | 2015-10-22 | Анализ модуляторов |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201890081A EA201890081A1 (ru) | 2015-06-18 | 2015-10-22 | Механизм действия |
EA201890078A EA201890078A1 (ru) | 2015-06-18 | 2015-10-22 | Антитело |
EA201890082A EA201890082A1 (ru) | 2015-06-18 | 2015-10-22 | Эпитоп антитела |
Country Status (16)
Country | Link |
---|---|
US (11) | US10969393B2 (ru) |
EP (8) | EP3311170B1 (ru) |
JP (12) | JP6781718B2 (ru) |
KR (2) | KR20180048571A (ru) |
CN (6) | CN108139407B (ru) |
AU (2) | AU2015398985A1 (ru) |
CA (5) | CA2987827C (ru) |
CL (2) | CL2017003189A1 (ru) |
EA (4) | EA201890081A1 (ru) |
ES (5) | ES2902415T3 (ru) |
GB (1) | GB201510758D0 (ru) |
IL (2) | IL256099B1 (ru) |
MX (2) | MX2017015481A (ru) |
PL (4) | PL3311169T3 (ru) |
PT (4) | PT3311170T (ru) |
WO (5) | WO2016202413A1 (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016239948B2 (en) | 2015-03-31 | 2022-03-17 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
WO2016168638A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
UY36629A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Indazolonas como moduladores de la señalización de tnf |
EP3288939A1 (en) | 2015-04-17 | 2018-03-07 | AbbVie Inc. | Tricyclic modulators of tnf signaling |
GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
WO2018060453A1 (en) | 2016-09-30 | 2018-04-05 | Vhsquared Limited | Compositions |
GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
CA3049728A1 (en) * | 2017-01-10 | 2018-07-19 | Eth Zurich | Inhibitors of g-protein-coupled receptor kinase 2 and their use |
EP3986931A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
EP3986571A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2647427B2 (ja) | 1987-04-24 | 1997-08-27 | 帝人株式会社 | 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
JP3771253B2 (ja) | 1988-09-02 | 2006-04-26 | ダイアックス コープ. | 新規な結合タンパク質の生成と選択 |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US4908372A (en) | 1988-10-13 | 1990-03-13 | Merrell Dow Pharmaceuticals Inc. | Antihistaminic piperidinyl benzimidazoles |
DE3843534A1 (de) | 1988-12-23 | 1990-07-12 | Basf Ag | Neue tnf-polypeptide |
US6498237B2 (en) | 1989-08-07 | 2002-12-24 | Peptech Limited | Tumor necrosis factor antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
GB9028123D0 (en) | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
EP0580737B1 (en) | 1991-04-10 | 2004-06-16 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
IT1249708B (it) | 1991-09-23 | 1995-03-09 | Tecnogen Scpa | Metodo per la determinazione del fattore di necrosi tumorale (tnf) in forma biologicamente attiva. |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
TW231291B (ru) | 1992-01-09 | 1994-10-01 | Janssen Pharmaceutica Nv | |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1994018325A1 (en) | 1993-02-03 | 1994-08-18 | N.V. Innogenetics S.A. | Tnf-alpha muteins and a process for preparing them |
CA2119089A1 (en) * | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
PT1231268E (pt) | 1994-01-31 | 2005-11-30 | Univ Boston | Bancos de anticorpos policlonais |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
DE4440613C1 (de) | 1994-11-14 | 1996-07-25 | Leica Ag | Vorrichtung und Verfahren zur Detektion und Demodulation eines intensitätsmodulierten Strahlungsfeldes |
TW453995B (en) | 1995-12-15 | 2001-09-11 | Novartis Ag | Certain alpha-substituted arylsulfonamido acetohydroxamic acids |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
CN1204230A (zh) | 1997-12-08 | 1999-01-06 | 李建安 | 一种手提电话机用防护罩及其制做方法 |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
WO2002018540A2 (en) | 2000-09-01 | 2002-03-07 | Biogen, Inc. | Pyridine derivatives useful as cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications |
CA2446193C (en) | 2001-06-05 | 2011-11-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
US6632810B2 (en) | 2001-06-29 | 2003-10-14 | Kowa Co., Ltd. | Cyclic diamine compound with condensed-ring groups |
JP2003040888A (ja) | 2001-07-30 | 2003-02-13 | Sankyo Co Ltd | イミダゾール誘導体 |
US20060078944A1 (en) | 2002-08-01 | 2006-04-13 | Jun Kuai | Methods and reagents relating to inflammation and apoptosis |
EP1570267B1 (en) | 2002-12-03 | 2011-10-12 | UCB Pharma, S.A. | Assay for identifying antibody producing cells |
EA008254B1 (ru) | 2003-05-09 | 2007-04-27 | Фармекса А/С | Детоксифицированный tnf и способ получения |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
PL1644412T5 (pl) | 2003-07-01 | 2019-01-31 | Ucb Biopharma Sprl | Modyfikowane fragmenty Fab przeciwciała |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
NZ599196A (en) | 2003-07-15 | 2014-01-31 | Amgen Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
US7268116B2 (en) | 2003-10-02 | 2007-09-11 | Genhunter Corp. | Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins |
TW200526780A (en) | 2004-01-06 | 2005-08-16 | Hayashibara Biochem Lab | TNF antagonists and TNF inhibitors comprising the same as the active ingredient |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
EP1888640B1 (en) | 2005-05-18 | 2012-03-14 | Ablynx N.V. | Improved nanobodies against tumor necrosis factor-alpha |
DE102005023617A1 (de) | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
WO2007060411A1 (en) | 2005-11-24 | 2007-05-31 | Ucb Pharma S.A. | Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r |
EP2162469A4 (en) * | 2007-05-21 | 2012-08-01 | Alderbio Holdings Llc | NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES |
US9056905B2 (en) * | 2007-05-21 | 2015-06-16 | Alderbio Holdings Llc | Antibodies to TNF-α and use thereof |
WO2009020848A2 (en) * | 2007-08-03 | 2009-02-12 | Alcon Research, Ltd. | RNAI-RELATED INHIBITION OF TNFα SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA |
EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
US9365644B2 (en) | 2008-04-23 | 2016-06-14 | Epitomics, Inc. | Anti-TNFα antibody |
KR20190133077A (ko) | 2008-06-25 | 2019-11-29 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | TNFα를 저해하는 안정한 가용성 항체 |
MX2011005363A (es) | 2008-11-20 | 2011-08-12 | Panacea Biotec Ltd | Peptidos para inhibicion del factor alfa de necrosis tumoral y usos de los mismos. |
JP2010172307A (ja) | 2009-01-30 | 2010-08-12 | Saitama Medical Univ | 関節リウマチに対する可溶性TNFα/LTαレセプター薬の薬効予測方法、及び薬効予測装置 |
WO2010118404A2 (en) | 2009-04-09 | 2010-10-14 | California Institute Of Technology | Methods for creating or identifying compounds that bind tumor necrosis factor alpha |
RU2595379C2 (ru) | 2009-04-16 | 2016-08-27 | АббВай Биотерапеутикс Инк. | АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ |
KR20150038556A (ko) | 2010-04-07 | 2015-04-08 | 애브비 인코포레이티드 | TNF-α 결합 단백질 |
US8377441B2 (en) | 2010-08-03 | 2013-02-19 | National Cheng Kung University | Treating breast cancer with anti-IL-19 antibody |
AU2011320140C1 (en) * | 2010-10-30 | 2019-12-12 | Kindex Pharmaceuticals, Inc. | Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(-3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods |
AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
US20140112929A1 (en) | 2011-06-17 | 2014-04-24 | Glaxo Group Limited | Tumour necrosis factor receptor 1 antagonists |
CN103930126A (zh) * | 2011-08-12 | 2014-07-16 | Bsrc亚历山大.弗莱明 | Tnf超家族三聚化的抑制剂 |
US9550737B2 (en) * | 2012-06-11 | 2017-01-24 | Ucb Biopharma Sprl | TNF -α modulating benzimidazoles |
WO2014001557A1 (en) | 2012-06-28 | 2014-01-03 | Ucb Pharma S.A. | A method for identifying compounds of therapeutic interest |
GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
CN104619709B (zh) | 2012-07-13 | 2016-11-09 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的咪唑并吡啶衍生物 |
WO2014040076A1 (en) | 2012-09-10 | 2014-03-13 | Xencor | Methods of treating neurological diseases |
AU2014215639B2 (en) | 2013-01-25 | 2017-03-23 | Thymon, Llc | Compositions for selective reduction of circulating bioactive soluble TNF and methods for treating TNF-mediated disease |
MX2015012138A (es) | 2013-03-12 | 2016-06-02 | Anellotech Inc | Regeneracion de catalizador de pirolisis rapida catalitica. |
TW201536810A (zh) | 2013-07-15 | 2015-10-01 | Novo Nordisk As | 結合尿激酶纖維蛋白溶酶原活化物之抗體 |
GB201321733D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321736D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
RU2685234C1 (ru) | 2013-12-09 | 2019-04-17 | Юсб Байофарма Спрл | Конденсированные бициклические гетероароматические производные в качестве модуляторов активности tnf |
US9920052B2 (en) | 2013-12-09 | 2018-03-20 | Ucb Biopharma Sprl | Imidazopyridine derivatives as modulators of TNF activity |
GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321748D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321731D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321735D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
GB201321749D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321745D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
GB201321740D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321744D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321730D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321734D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
GB201321732D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321742D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
BR112017006669B1 (pt) | 2014-10-03 | 2023-04-18 | Ucb Biopharma Sprl | Derivados de imidazol pentacíclico fundido, composição farmacêutica compreendendo os mesmos e uso dos mesmos |
TWI703156B (zh) | 2015-01-30 | 2020-09-01 | 學校法人埼玉醫科大學 | 抗alk2抗體 |
CA2982446A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds useful as inhibitors of tnf |
JP6779899B2 (ja) | 2015-03-18 | 2020-11-04 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Tnf阻害剤として有用なヘテロ環式化合物 |
EA032315B1 (ru) | 2015-03-18 | 2019-05-31 | Бристол-Маерс Сквибб Компани | Замещенные трициклические гетероциклические соединения |
WO2016168638A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
EP3288939A1 (en) | 2015-04-17 | 2018-03-07 | AbbVie Inc. | Tricyclic modulators of tnf signaling |
UY36629A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Indazolonas como moduladores de la señalización de tnf |
GB201509885D0 (en) | 2015-06-08 | 2015-07-22 | Ucb Biopharma Sprl | Therapeutic agents |
GB201509893D0 (en) | 2015-06-08 | 2015-07-22 | Ucb Biopharma Sprl | Therapeutic agents |
GB201509888D0 (en) | 2015-06-08 | 2015-07-22 | Ucb Biopharma Sprl | Therapeutic agents |
GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
US10335392B2 (en) | 2015-08-03 | 2019-07-02 | Bristol-Myers Squibb Company | Cyclic compounds useful as modulators of TNF α |
BR112018001960A2 (pt) | 2015-08-03 | 2018-09-18 | Bristol-Myers Squibb Company | compostos heterocíclicos úteis como moduladores de tnf alfa |
CN109219608B (zh) | 2016-04-01 | 2021-12-21 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合五环咪唑衍生物 |
US10654861B2 (en) | 2016-04-01 | 2020-05-19 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives as modulators of TNF activity |
BR112018069937A2 (pt) | 2016-04-01 | 2019-02-05 | Sanofi Sa | derivados de imidazol hexacíclicos fundidos como moduladores de atividade do tnf |
CN109195969B (zh) | 2016-04-01 | 2021-12-21 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合五环咪唑衍生物 |
GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
-
2015
- 2015-06-18 GB GBGB1510758.4A patent/GB201510758D0/en not_active Ceased
- 2015-10-22 PT PT157843681T patent/PT3311170T/pt unknown
- 2015-10-22 EA EA201890081A patent/EA201890081A1/ru unknown
- 2015-10-22 EA EA201890078A patent/EA201890078A1/ru unknown
- 2015-10-22 ES ES15784370T patent/ES2902415T3/es active Active
- 2015-10-22 CA CA2987827A patent/CA2987827C/en active Active
- 2015-10-22 EP EP15784368.1A patent/EP3311170B1/en active Active
- 2015-10-22 CA CA2987698A patent/CA2987698C/en active Active
- 2015-10-22 PL PL15784069T patent/PL3311169T3/pl unknown
- 2015-10-22 ES ES15784368T patent/ES2895552T3/es active Active
- 2015-10-22 AU AU2015398985A patent/AU2015398985A1/en not_active Abandoned
- 2015-10-22 WO PCT/EP2015/074524 patent/WO2016202413A1/en active Application Filing
- 2015-10-22 EP EP21192200.0A patent/EP3960759A1/en active Pending
- 2015-10-22 WO PCT/EP2015/074532 patent/WO2016202415A1/en active Application Filing
- 2015-10-22 EP EP15784370.7A patent/EP3311171B1/en active Active
- 2015-10-22 JP JP2017565155A patent/JP6781718B2/ja active Active
- 2015-10-22 MX MX2017015481A patent/MX2017015481A/es unknown
- 2015-10-22 ES ES15784066T patent/ES2836769T3/es active Active
- 2015-10-22 JP JP2017565114A patent/JP7336178B2/ja active Active
- 2015-10-22 US US15/736,535 patent/US10969393B2/en active Active
- 2015-10-22 CA CA2988516A patent/CA2988516A1/en active Pending
- 2015-10-22 MX MX2017015757A patent/MX2017015757A/es unknown
- 2015-10-22 JP JP2017565189A patent/JP6948954B2/ja active Active
- 2015-10-22 PL PL15784370T patent/PL3311171T3/pl unknown
- 2015-10-22 WO PCT/EP2015/074491 patent/WO2016202412A1/en active Application Filing
- 2015-10-22 US US15/736,614 patent/US10775385B2/en active Active
- 2015-10-22 EA EA201890082A patent/EA201890082A1/ru unknown
- 2015-10-22 PT PT157843707T patent/PT3311171T/pt unknown
- 2015-10-22 CA CA2987823A patent/CA2987823C/en active Active
- 2015-10-22 JP JP2017565174A patent/JP6951256B2/ja active Active
- 2015-10-22 EA EA201890080A patent/EA201890080A1/ru unknown
- 2015-10-22 ES ES15784069T patent/ES2895486T3/es active Active
- 2015-10-22 EP EP15784067.9A patent/EP3311168B1/en active Active
- 2015-10-22 KR KR1020187001568A patent/KR20180048571A/ko unknown
- 2015-10-22 EP EP21194582.9A patent/EP3995831A1/en not_active Withdrawn
- 2015-10-22 AU AU2015398984A patent/AU2015398984B2/en active Active
- 2015-10-22 PL PL15784067.9T patent/PL3311168T3/pl unknown
- 2015-10-22 EP EP21201892.3A patent/EP3988936A1/en not_active Withdrawn
- 2015-10-22 US US15/736,558 patent/US11022614B2/en active Active
- 2015-10-22 EP EP15784066.1A patent/EP3311167B1/en active Active
- 2015-10-22 CN CN201580080990.7A patent/CN108139407B/zh active Active
- 2015-10-22 PL PL15784368T patent/PL3311170T3/pl unknown
- 2015-10-22 CN CN201580081000.1A patent/CN108055865B/zh active Active
- 2015-10-22 CN CN202010405385.5A patent/CN111574517B/zh active Active
- 2015-10-22 JP JP2017565173A patent/JP6659030B2/ja active Active
- 2015-10-22 PT PT157840679T patent/PT3311168T/pt unknown
- 2015-10-22 WO PCT/EP2015/074527 patent/WO2016202414A1/en active Application Filing
- 2015-10-22 CN CN201580081026.6A patent/CN107810419B/zh active Active
- 2015-10-22 PT PT157840695T patent/PT3311169T/pt unknown
- 2015-10-22 CN CN201580080984.1A patent/CN107771286B/zh active Active
- 2015-10-22 WO PCT/EP2015/074490 patent/WO2016202411A1/en active Application Filing
- 2015-10-22 ES ES15784067T patent/ES2948915T3/es active Active
- 2015-10-22 EP EP15784069.5A patent/EP3311169B1/en active Active
- 2015-10-22 US US15/736,336 patent/US10883996B2/en active Active
- 2015-10-22 CA CA2988723A patent/CA2988723A1/en not_active Abandoned
- 2015-10-22 CN CN201580080985.6A patent/CN108290945B/zh active Active
- 2015-10-22 IL IL256099A patent/IL256099B1/en unknown
- 2015-10-22 KR KR1020187001566A patent/KR102599907B1/ko active IP Right Grant
- 2015-10-22 US US15/736,520 patent/US10705094B2/en active Active
-
2017
- 2017-12-04 IL IL256097A patent/IL256097A/en unknown
- 2017-12-13 CL CL2017003189A patent/CL2017003189A1/es unknown
- 2017-12-18 CL CL2017003246A patent/CL2017003246A1/es unknown
-
2019
- 2019-08-27 JP JP2019154528A patent/JP6752344B2/ja active Active
-
2020
- 2020-05-26 US US16/883,859 patent/US11448655B2/en active Active
- 2020-09-04 US US17/013,326 patent/US11674967B2/en active Active
- 2020-10-16 JP JP2020174314A patent/JP2021038222A/ja active Pending
- 2020-10-16 US US17/072,665 patent/US20210140972A1/en active Pending
-
2021
- 2021-01-07 US US17/143,719 patent/US20210132079A1/en not_active Abandoned
- 2021-02-12 JP JP2021020352A patent/JP2021109880A/ja active Pending
- 2021-05-19 US US17/325,036 patent/US20220074947A1/en active Pending
- 2021-06-08 JP JP2021095909A patent/JP2021153592A/ja not_active Abandoned
- 2021-09-24 JP JP2021155537A patent/JP7159420B2/ja active Active
-
2022
- 2022-08-30 US US17/823,356 patent/US20230194541A1/en active Pending
-
2023
- 2023-01-06 JP JP2023001089A patent/JP2023052250A/ja active Pending
- 2023-03-23 JP JP2023046164A patent/JP2023100010A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201890080A1 (ru) | Анализ модуляторов | |
EA202190485A1 (ru) | Соединения, модулирующие fxr (nr1h4) | |
CL2018001667A1 (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
ECSP18041833A (es) | Anticuerpos que se unen específicamente a pd-1 y sus usos | |
MX2018015592A (es) | Anticuerpos inhibidores de puntos de control biespecificos. | |
EA201691974A1 (ru) | Антитела против ox40 и способы их применения | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
ECSP18033227A (es) | Anticuerpos agonistas que se unen específicamente a CD40 humana y métodos de uso | |
EA201791002A1 (ru) | Новые соединения, модулирующие fxr (nr1h4) | |
EA201891344A1 (ru) | Новые агонисты рецептора апелина и способы применения | |
EA202092435A3 (ru) | Моноклональные антитела против bcma | |
EA201890712A1 (ru) | Антитела к про-/латентному миостатину и их применения | |
BR112017011932A8 (pt) | Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso | |
EA201500995A1 (ru) | Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения | |
EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201691541A1 (ru) | Новые анти-baff антитела | |
EA201490454A1 (ru) | Тернесит в качестве активатора для латентно-гидравлических и пуццолановых веществ | |
EA201591615A1 (ru) | Замещенные ксантины и способы их применения | |
BR112015022123A8 (pt) | Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit | |
EA201500801A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
ECSP18008922A (es) | Anticuerpos anti-CD154 y métodos de uso de estos | |
EA201690099A1 (ru) | Устойчивая жидкая композиция, содержащая amg-416 (велкальцетид) | |
EA201690992A1 (ru) | Антитела, специфичные к fcrn | |
MX2017007381A (es) | Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano. |